Dasiglucagon is under clinical development by Zealand Pharma and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Dasiglucagon’s likelihood of approval (LoA) and phase transition for Hyperinsulinemia took place on 20 May 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Dasiglucagon Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Dasiglucagon overview

Dasiglucagon (Zegalogue) is an anti hypoglycemic agent. It is formulated as solution for subcutaneous route of administration. Zegalogue is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.

Dasiglucagon (ZP-4207) is under development for the treatment of congenital hyperinsulinemia (CHI). The drug candidate is administered intravenously, intramuscularly and subcutaneously as a liquid formulation. It was also under development for type 1 diabetes and severe hypoglycemia associated with diabetes and mild to moderate hypoglycemia as glucagon rescue pen, pump use and multiple dose use.

Zealand Pharma overview

Zealand Pharma (Zealand) is a biotechnology company. It discovers, designs and develops peptide-based medicines that target specialty diseases. The company’s product portfolio comprises glepaglutide which is a long-acting GLP-2 analog in development for the treatment of short bowel syndrome and dasiglucagon is used against type 1 diabetes and congenital hyperinsulinism. It also offers GLP1-GLU which is used against several cardio-metabolic diseases such as heart disease, ischemic stroke and liver diseases. Zealand conducts research and development and in-licensing programs. It has operations in Denmark and the US. ealand is headquartered in Soeborg, Denmark.

Quick View Dasiglucagon LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Dasiglucagon
Administration Pathway
  • Intramuscular
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Metabolic Disorders
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.